170 related articles for article (PubMed ID: 38782182)
41. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
[TBL] [Abstract][Full Text] [Related]
42. Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis V; Papatheodoridis GV
Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
[TBL] [Abstract][Full Text] [Related]
43. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
[TBL] [Abstract][Full Text] [Related]
44. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
45. Metabolic Dysfunction-Associated Steatohepatitis Detected by Neutrophilic Crown-Like Structures in Morbidly Obese Patients: A Multicenter and Clinicopathological Study.
Fan M; Song E; Zhang Y; Zhang P; Huang B; Yan K; Yang W; Chakrabarti S; Mahajan H; Yan S; Xu Y; Hua S; Liu W; Wang C; Xu A; Ye D
Research (Wash D C); 2024; 7():0382. PubMed ID: 38812532
[TBL] [Abstract][Full Text] [Related]
46. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
47. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
48. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
49. FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.
Harrison SA; Rolph T; Knot M; Dubourg J
J Hepatol; 2024 May; ():. PubMed ID: 38710230
[TBL] [Abstract][Full Text] [Related]
50. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
[TBL] [Abstract][Full Text] [Related]
51. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
[TBL] [Abstract][Full Text] [Related]
52. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
[TBL] [Abstract][Full Text] [Related]
53. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
54. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
[TBL] [Abstract][Full Text] [Related]
55. MetALD: Does it require a different therapeutic option?
Marek GW; Malhi H
Hepatology; 2024 May; ():. PubMed ID: 38820071
[TBL] [Abstract][Full Text] [Related]
56. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
[TBL] [Abstract][Full Text] [Related]
57. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms.
Richter MM; Kemp IM; Heebøll S; Winther-Sørensen M; Kjeldsen SAS; Jensen NJ; Nybing JD; Linden FH; Høgh-Schmidt E; Boesen MP; Madsbad S; Schiødt FV; Nørgaard K; Schmidt S; Gluud LL; Haugaard SB; Holst JJ; Nielsen S; Rungby J; Wewer Albrechtsen NJ
Metabolism; 2024 Jul; 156():155915. PubMed ID: 38631460
[TBL] [Abstract][Full Text] [Related]
58. Emerging therapies for MASLD and their impact on plasma lipids.
Nguyen M; Asgharpour A; Dixon DL; Sanyal AJ; Mehta A
Am J Prev Cardiol; 2024 Mar; 17():100638. PubMed ID: 38375066
[TBL] [Abstract][Full Text] [Related]
59. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
60. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
